Imagine that all patient data from all clinical trials was made available for independent analysis. And it was void of patient identities to quiet any concerns about privacy. Now imagine the opportunity for medical discovery. That might be what the future looks like for the pharmaceutical industry.
This complimentary conclusions article summarizes the Clinical Trial Data Transparency Forum that was held in October 2013. Pharmaceutical leaders from across the industry gathered to share their viewpoints on data transparency, including opportunities and challenges.
This article is a compendium of general discussion from the forum and covers topics like:
- Process and protocol.
- Permission and privacy.
- IT platforms.
Have a SAS profile? To complete this form automatically: Log In